Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer

International Journal of Gynecological Cancer

Volumn 12, Issue 1, 2002, Pages 66-73

  Hasenburg, A ^a,b   Fischer, D C ^d   Tong, X W ^a,b   Rojas Martinez, A ^b   Nyberg Hoffman, C ^b   Orlowska Volk, M ^a   Kohlberger, P ^a   Kaufman, R H ^b   Ramzy, I ^b   Aguilar Cordova, E ^c   Kieback, D G ^a,b,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acyclovir; Dedifferentiation; Desmoplastic reaction; Gene therapy; Ovarian cancer; Topotecan

Indexed keywords

THYMIDINE KINASE; TOPOTECAN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; FEMALE; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS; OVARY CANCER; PRIORITY JOURNAL;

ADENOVIRUSES, HUMAN; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, ENDOMETRIOID; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, PAPILLARY; DNA PRIMERS; DNA, VIRAL; FEMALE; FIBROSIS; GENE THERAPY; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; SECOND-LOOK SURGERY; SIMPLEXVIRUS; THYMIDINE KINASE; TOPOTECAN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036194178     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.01068.x     Document Type: Article

References (47)

1. Epidemiological and molecular aspects of ovarian cancer risk
2. Cancer statistics, 2000
3. Estimates of the worldwide frequency of sixteen major cancers in 1980
4. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
5. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy
6. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings
7. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
8. Gene therapy and ovarian cancer: A review
9. Prodrug-activating systems in suicide gene therapy
10. Adenovirus mediated tymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to selected chemotherapeutic agents
11. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer
12. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor
13. Oncoprotein networks
14. Prognostic factors in ovarian cancer
15. Predicting response to cancer chemotherapy: The role of p53
16. The hallmarks of cancer
17. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
18. Tumor suppressor genes
19. Cell death and cancer therapy
20. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer
21. Differentiation of T cell lymphokine gene expression: The in vitro acquisition of T cell memory
22. Distribution, persistency, toxicity, and lack of replication of an E1A-recombinant adenoviral vector after intracardiac delivery in the cotton rat
23. Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele specific oligonucleotide probes
24. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase
25. Antigen retrieval immunohistochemistry: Practice and development
26. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
27. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo
28. Safety of in vivo adenovirus-mediated thymidine kinase treatment of oral cancer
29. The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study
30. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
31. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
32. Adenovirusmediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer
33. Stage IV ovarian cancer: Impact of surgical debulking
34. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer
35. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy
36. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model
37. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice
38. Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat)
39. Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer 1980-97
40. Interim analysis of a phase III randomized trial of doxil/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer
41. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
42. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
43. Secondary cytoreductive surgery for recurrent ovarian cancer
44. Role of secondary surgery in relapsed ovarian cancer
45. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
46. Conditionally replicating herpes vectors for cancer therapy
47. Phase I/II gene therapy in recurrent ovarian cancer with intraperitoneal recombinant adenoviral human p53